维普期刊资源整合服务平台（V6.5）

113篇 您的检索式：作者名="DAHUT"

选中清除导出查看参考文献查看引证文献引用追踪共6页首页上一页第1页下一页末页 /6 跳转

	题名	作者	年代	出处	被引量
1	Eligibility and response guidelines for phase Ⅱ clinical trials in androgen-independent prostate cancer:recommendations from the Prostate-Specific Antigen Working Group显示文摘	Bubley GJ Carducci M Dahut W	1999	J Clin Oncol1999，17，：	1
2	Angiogene- sis inhibition in prostate cancer: current uses and future promises 显示文摘	ARAGON CHING J B MADAN R A DAHUT W L	2010	JOncol2010，2010，36：	1
3	Risks of proteinuria and hypertension with bevacizumab,an antibody against vascu-lar endothelial growth factor:systematic review and meta-analysis显示文摘	Zhu X Wu S Dahut WL		0，，02：	1
4	Risks of proteinuria and hy- pertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analy- sis 显示文摘	Zhu X Wu S Dahut WL	2007	Am J Kidney Dis2007，49，2：	1
5	Randomized phase' ]/trial of docetaxel plus thalido- mide in androgen-independent prostate cancer显示文摘	Dahut WL	2004	J Clin Oncol2004，22，3：	1
6	Eligibility and response guidelines for phase Ⅱ clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group 显示文摘	Carducci M Dahut W	1999	J Clin Oncol1999，17，11：	1
7	Phase I clinical trial of oral 2-methoxyestradiol, an antiangiogenic and apoptotic agent, in patients with solid tumors 显示文摘	Dahut WL Lakhani NJ Gulley JL	2006	Cancer Biol Ther2006，5，1：	1
8	Quantitative determination of total and unbound paclitaxel in human plasma following Abraxane treatment 显示文摘	Gardner E R Dahut W Figg W D	2008	J Chromatogr B Analyt Technol Biomed Life Sci2008，862，：	1
9	Randomised phase Ⅱ trial of docetaxel plus thalidomide in androgen-independent prosrate cancer 显示文摘	Dahut WL Gulley JL Arlen PM	2004	J Clin Oncol2004，22，13：	1
10	VEGF inhibitors and prostate cancer therapy显示文摘	Aragon-Ching JB Dahut WL	2009	Curr Mol Pharmacol2009，2，2：	1
11	Determination of the antiangiogenesis agent 2-methoxyestradiol in human plasma by liquid chromatography with ultraviolet detection显示文摘	Lakhani N J Sparreboom A Dahut WL	2004	J Chromatogr B Analyt Technol Biomed Life Sci2004，806，2：	1
12	Phase I study of a vaccine using recombinant vaccinia virus expressing PSA (rV-PSA) in patients with metastatic androgen-independent prostate cancer显示文摘	Gulley J Chen AP Dahut W	2002	Prostate2002，53，2：	1
13	Risks of proteinuria and hyperten- sion with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis显示文摘	Zhu X Wu S Dahut W L	2007	Am J Kid- ney Dis2007，49，2：	1
14	Eligibility and response guidelines for phase Ⅱ clinical trials in androgenindependent prostate cancer:recommendations from the Prostate-Specific Antigen Working Group显示文摘	Carducci M Dahut W	1999	J Clin Oncol1999，17，：	1
15	Eligibility and response guidelines for phase 1I clinical trials in androgen independent prostate cancer: recommendations t'rom the prostate-specific antigen working group显示文摘	Bubley GJ Carducci M Dahut W	1999	J Clin Oncol1999，，：	1
16	Randomized phase Ⅱ trim of docetaxel plus thalidomide in androgen-independent prostate cancer显示文摘	Dahut WL Gulley JL Arlen PM	2004	J Clin Oncol2004，22，13：	1
17	Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth fac- tor : systematic review and meta-analysis 显示文摘	Zhu X Wu S Dahut WL	2007	Am J Kidney Dis2007，49，2：	1
18	Angiogenesis inhibition in the treatment of prostate cancer显示文摘	MADAN RAVI A DAHUT	2009	Anti-cancer Agents Med Chem2009，9，10：	1
19	Eligibility and response guidelines for phase Ⅱ clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group显示文摘	Buhley G J Carducci M Dahut W	1999	J Clin Oncol1999，17，：	1
20	The combination of antiangiogenic and cytotoxic agents in the treatment of prostate cancer 显示文摘	Retter A S Figg W D Dahut W L	2003	Clin Prostate Cancer2003，2，3：	1

返回顶部每页显示：

共6页首页上一页第1页下一页末页 /6 跳转

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费

用户提示